Antiretroviral therapy in HIV patients: Aspects of metabolic complications and mitochondrial toxicity

Netherlands Journal of Medicine

Volumn 61, Issue 11, 2003, Pages 393-403

  ter Hofstede, H J M ^a   Burger, D M ^a   Koopmans, P P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BIOMATERIAL; BOTULINUM TOXIN; DIDANOSINE; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAMIVUDINE; LEPTIN; METFORMIN; NELFINAVIR; NEVIRAPINE; ORAL ANTIDIABETIC AGENT; POLYUNSATURATED FATTY ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VITAMIN; ZALCITABINE; CARNITINE; RIBOFLAVIN; THIAMINE; UBIQUINONE;

ABDOMINAL PAIN; ANEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; ESTHETIC SURGERY; FATTY LIVER; HEART ARRHYTHMIA; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERVENTILATION; IMPLANTATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; LIPOATROPHY; LIVER FAILURE; MALAISE; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MYOPATHY; NAUSEA; NEUROPATHY; OBESITY; PANCREATITIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; VIRUS LOAD; VOMITING; CLINICAL FEATURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LIPODYSTROPHY; MORBIDITY; MORTALITY; PREVALENCE; VIRUS REPLICATION; CHEMICALLY INDUCED DISORDER; PATHOPHYSIOLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MITOCHONDRIAL DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 1642617616     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Dieleman J, Jambroes M, Gijssens IC, et al., on behalf of the ATHENA Study Cohort Group. Determinants of recurrent toxicity-driven Switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS 2002;16:737-45.
3. Struble KA, Pratt RD, Gitterman SR. Toxicity of antiviral agents. Am J Med 1997;102:65-7.
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
5. Brinkman K, Hofstede HJM ter, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998:351:867-70.
7. Carr A. HIV protease inhibitors-induced lipodystrophy syndrome. AIDS Rev 1999:1:29-36.
8. Blanco F, Carr A. Lipodystrophy syndrome: Diagnostic, clinic and therapeutic aspects. AIDS Rev 2001;3:98-105.
9. Saint-Marc T, Partisani M, Piozot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
10. Saint-Marc T, Partisani M, Piozot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
11. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32.
12. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30:S135-42.
13. Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998:339:1296.
14. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
15. Dieleman J. Risk of lipodystrophy is highest after prolonged exposure to stavudine containing antiretroviral treatment. The ATHENA cohort. Thesis: Safety aspects of HIV-protease inhibitors; chapter 3.2:108-22.
16. Chang K, Kim J, Song Y, Hong S, Lee H, Lim S. Does race protect an Oriental population from developing lipodystrophy in HIV-infected individuals on HAART? J Infect 2002;44:33-8.
17. Saint-Marc T, Partisani M, Piozot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
18. Carr A, Samaras K, Thoridottir A, Kaufmann G, Chisholm DJ, Dooper DA. Diagnosis, prediction and the natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999;353:2093-9.
19. Cohen C, Shen Y, Rode R, et al. Effect of nucleoside intensification on prevalence of morphologic abnormalities at year 5 of ritonavir plus saquinavir therapy in an HIV-infected cohort [Abstract 683]. 9th CROI. Seattle 2002.
20. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001;27(3):237-44.
21. McComsey G. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. AIDS Rev 2002;4:140-7.
22. Valk M van der, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-55.
23. Carr A, Samaras K, Chisholm D, Cooper D. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998;351:1881-3.
24. Barbaro G, Klatt E. HIV infection and the cardiovascular system. AIDS Rev 2002;4:93-103.
25. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359(9311):1026-31.
26. Kreier F, Fliers E, Voshol P, et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J Clin Invest 2002;110(9):1243-50.
27. Valk M van der, Reiss P, Leth FC van, et al. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab 2002;87(11):5066-71.
28. Christeff N, Melchior JC, Truchis P de, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999;13(16):2251-60.
29. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999;13(16):2261-7.
30. Behrens GM, Boerner AR, Weber K, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. Clin Invest 2002;110(9):1319-27.
31. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002;16(6):925-6.
32. Ben-Romano R, Rudich A, Torok D, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003;17(1):23-32.
33. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet 1999;354:1112-5.
34. Zaera MG, Miro O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001;15:1643-51.
35. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17(9):1329-38.
36. Walker U, Bickel M, Walker UA, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002;29(2):117-21.
37. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:11-8.
38. Holmberg S, Moorman A, Williamson J, et al, and the HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
39. Bozzette S, Ake C, Tam H, Chang S, Louis T. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
40. Friis-Moller N, Weber R, Reiss P, et al, for the DAD study group. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: Results from the DAD study. AIDS 2003;17(8):1179-93.
41. Stein J, Klein M, Bellehumeur L, et al. Use of human immunodeficiency virus-1 protease inhibitors is associates with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-62.
42. Passalaris J, Sepkowitz K, Glesby M. Coronary artery disease and Human immunodeficiency virus infection. Clin Infect Dis 2000;31:787-97.
43. Acevedo M, Sprecher D, Clabrese L, et al. Pilot study of coronary atherosclerotic risk factors and plaque burden in HIV patients: 'A call for cardiovascular prevention.' Atherosclerosis 2002;163:349-54.
44. Barbaro G. HIV infection, antiretroviral therapy and cardiovascular risk. J Cardiovasc Risk 2002;9:295-300.
45. Tashima K, Bausserman L, Alt E, Flanigan T. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003;4:29-36.
46. Valk M van der, Kastelein J, Murphy R, et al, on behalf of the Atlantic study. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14.
47. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505.
48. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycaemia, hyperlipidaemia and lipodystrophy. Arch Intern Med 2000;160:2050-6.
49. HIV lipodystrophy case definition study group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-35.
50. Kaul DR, Cinti SK, Carver PL, et al. HIV protease inhibitors; Advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999;19(3):281-98.
51. Sluys TEMS, Ende ME van der, Swart GR, Berg JWO van der, Wilson JHP. Body composition in patients with acquired immunodeficiency syndrome: A validation study of Bioelectric Impedance Analysis. J Parenteral Enteral Nutr 1993;17:404-6.
52. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 2003:77:490-4.
53. Carr A, Law M, on behalf of the HIV Lipodystrophy Case Definition Study group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33:571-6.
54. Martinez E, Bianchi L, Garcia-Viejo M, Bru C, Gatell J. Sonographic assessment of regional fat in HIV-1-infected people. Lancet 2000;356:1412-3.
55. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 200;284(4):472-7.
56. Gelato M, Mynarcik D, Quick J, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone; a pilot study. J Acquir Immune Defic Syndr 2002;31:163-70.
57. Walli R, Michl G, Mühlbayer D, Vrinkmaan L, Goebel F. Effects of roglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000;199(5):253-62.
58. Riddle T, Fichtenbaum C, Hui D. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J Acquir Immune Defic Syndr 2003;33:564-70.
59. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement for lipodystrophy. N Engl J Med 2002;346:570-8.
60. Petersen K, Oral E, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002:109(10):1345-50.
61. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 2001;41:181-8.
62. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BC. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitors. AIDS 2001;15(12):1503-8.
63. Drechsler H, Powderly W. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002;35:1219-30.
64. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipodystrophy; A randomised trial. JAMA 2002;288:207-15.
65. Estrada V, Villar N de, Martinez Larrad M, Gonzalez Lopez A, Fernandez C, Serrano-Rios M. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipodystrophy. Clin Infect Dis 2002;35:69-76.
66. Wensing A, Reedijk M, Richter C, Boucher C, Borleffs J. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS 2001;15:2191-3.
67. Murphy R, Smith W. Switch studies; a review. HIV Med 2002;3:146-55.
68. Opravil M, Hirshel B, Lazzarin A, et al, Swiss cohort study. A randomised trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.
69. Negredo E, Cruz L, Paredes R, et al. Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting vial suppression. Clin Infect Dis 2002;34:504-10.
70. Cheonis N. New Fill to treat facial wasting. Bull Exp Treat AIDS 2002;15(2);10-5.
71. Dalakas MC, Illa II, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Eng J Med 1990;322:1098-105.
72. Swartz MN. Mitochondrial toxicity - New adverse drug effects. N Eng J Med 1995;333:1146-8.
73. Peters BS, Winer J, Landon DN, Stotter A, Pinching AJ. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. QJM 1993;86:5-15.
74. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
75. Moyle CJ. Toxicity of antiretroviral nucleoside and nucleotide analogues. Is mitochondrial toxicity the only mechanism? Drug Safety 2000;23:467-81.
76. Valk M van der, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-55.
77. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996;51:846-64.
78. Perry CM, Balfour JA. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 1996;52:928-62.
79. Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997;53:1054-80.
80. Hoetelmans RM, Burger DM, Meenhorst PL, Beijnen JH. Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996;30:314-27.
81. Wilde MI, Langtry HD. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;46:515-78.
82. Hofstede HJM ter, Marie S de, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000;11:611-6.
83. Hofstede HJM ter, Brinkman K. Mitochondrial toxicity owing to nucleoside reverse transcriptase inhibitors: importance of clinical features and early diagnosis. Int Antiviral News 1999;7:148-51.
84. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:(8740):508-10.
85. Peters BS, Winer J, Landon DN, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. QJM 1993;86:(1):5-15.
86. Chariot P, Gherardi R. Myopathy and HIV infection. Curr Opin Rheumatol 1995;7(6):497-502.
87. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine toxicity. N Engl J Med 1990;322:1098-105.
88. Lai KK, Gang DL, Zawacki JK, et al. Fulminant hepatic failure associated with 2′3′-dideoxyinosine (ddl). Ann Intern Med 1991;115:283-4.
89. Chariot P, Gherardi R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. Neuromuscul Disord 1991;1:(5):357-63.
90. Chariot P, Monnet I, Gherardi R. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann Neurol 1993;34(4):561-5.
91. Munnich A, Rustin P, Rötig A, et al. Clinical aspects of mitochondrial disorders. J Inherit Metab Dis 1992;15:448-55.
92. Chariot P, Monnet I, Mouchet M, et al. Determination of the blood lactate: pyruvate ratio as a non-invasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum 1994;37(4):583-6.
93. Sundar K, Suarez M, Banogon PE, Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997;25:1425-30.
94. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: Report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-46.
95. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with treatment in an HIV patient: a case report [Letter]. AIDS 1997;11:1294-6.
96. Lonergan TJ, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactataemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-6.
97. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: A report of five cases. Clin Infect Dis 2000;30:198-200.
98. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases. Ann Intern Med 2001;133:192-6.
99. John M, Moore CB, James IR. Chronic hyperlactatemia in HIV infected patients on antiretroviral therapy. AIDS 2001;15:717-23.
100. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: The Swiss Cohort Study. Clin Infect Dis 2001;33:1931-7.
101. Gerard Y, Maulin L, Yazdanpanah V. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-30.
102. Delgado J, Harris M, Tesiorowski A, Montaner JSG. Symptomatic elevations of lactic acidosis and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis 2001;33:2072-4.
103. Vrouwenraets S, Treskens M, Regez RM, et al. Hyperlactatemia in HIV-infected patients: the role of NRTI treatment [Abstract 625]. 8th Conference on retroviruses and opportunistic infections. Chicago, 2001.
104. Brew B, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy [Abstract 9]. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001.
105. Brinkman K. Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. Clin Infect Dis 2000;31:167-9.
106. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-7.
107. Boffito M, Marietti C, Audagnotto S, Raiter R, Di Perri C. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2002;34:558-9.
108. Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC) on cultured human muscle cells. J Neuol Sci 1997;149:19-25.
109. Bartley PB, Westacott L, Boots RJ, et al. Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy. AIDS 2001;15(3):419-20.
110. Côté HCF, Brumme ZL, Craib KJP, et al. Changes in mitochondrial DNA as marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
111. Walker U, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse transcriptase inhibitors. AIDS 2002;16:2165-73.
112. Vittecoq D, Jardel C, Barthelemy C, et al. Mitochondrial damage associated with long-term antiretroviral treatment; associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002;31:299-308.
113. Cossarizza A, Troiano L, Mussini C. Mitochondria and HIV infection; the first decade. J Biol Regul Homeost Agents 2002;16:18-24.
114. Dalakas M, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′ -dideoxycytidine (ddC). Lab Invest 2001;81:1537-44.
115. Shikuma C, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-9.
116. Casademont J, Barrientos A, Grau J, et al. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 1996;119:1357-64.
117. Tsai C, Doong S, Johns D, Driscoll J, Cheng V. Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem Pharmacol 1994;48:1477-81.
118. Arnaudo E, Dalakas M, Shanske S, Moreas C, DiMauro S, Schon E. Depletion of muscle DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-10.
119. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue induced lactic acidosis. Lancet 1998,;352:291-2.
120. Luzatti R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavin and severe lactic acidosis. Lancet 1999;353:901-2.
121. Przyrembel H. Therapy of mitochondrial disorders. J Inherit Metab Dis 1987;10(suppl 1):129-46.
122. Walker UA, Byrne F. The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Acta Neurol Scand 1995;92:273-80.
123. Semino Mora MC, Leon Monzon ME, Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. Lab Invest 1994;71:102-12.